Links

Homepage

Stock List

Search by Ticker

News

Login

Vertex Pharmaceuticals Incorpor (NASDAQ:VRTX)
Stock Analysis

VRTX272.99
▼ -0.13%-0.35

Stock Analysis

The following stock analysis is based on 7.7 years of data (i.e. since Nov 12, 2012). All the stock history has been downloaded.

Stock Exchange

Vertex Pharmaceuticals Incorpor trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the sector.

Current Status of Vertex Pharmaceuticals Incorpor

It is currently trading at $272.99 ($273.34 the previous day).

Financials

The next reporting date is in 73 days (2020 10 21).

CNN estimates profits for the upcoming quarter will be $2.28 per share ($1.5B). The current Canada / US exchange rate is 1.3382.



Over the past 12 months, $0 worth of shares have been purchased and $146144470 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 14.4% per year assuming steady exponential growth. The actual 5 year average is 16.84. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year233.1047128491631.2+ Above Average
2 year177.6451769911512.7- Below Average
3 year157.6339495798351.3+ Above Average
4 year104.19104838711.8- Below Average
5 year102.3781509434-12.8- Below Average
Vertex Pharmaceuticals Incorpor is projected by analysts to get to $315.00 within the next 12 months (15.4%), but preticted targets range from as high as $340.00 (24.5%) and as low as $245(-10.3%).

Risk

The worst drop it has had in recent years is -49.1%. It has a few bumps shape to the stock curve, which means the stock generally continues on a consistent trend and does not have to be checked often, but can have some variation during periods of volitility.

Stock shape test

DAYS AG0PRICE
10278.52DROPPING
30299.06DROPPING
60265.69RISING
150227.96RISING
365175.65RISING
800154RISING
1200116.34RISING
160086.78RISING
2000113.66DROPPING


With an average increase of 14.4% year over year, if Vertex Pharmaceuticals Incorpor is bought at the worst time, Stockmarketizer analysts estimate it will take 40.9 months before the stock will recover to the original purchase price. The P/E value is 34.46.

Tradingview BuySell Widget

Yahoo News Feed

Invest $5,000 in These 3 Stocks to Ride Out the Recession Without Worries

Sun, 02 Aug 2020 11:32:00 People across the world increased their online buying during the coronavirus-related lockdowns. As the largest e-commerce retailer in the world, Amazon was a prime beneficiary. The convenience of shopping online, combined with continued worries about COVID-19, should keep Amazon's sales ...... Read Full Article

Vertex (VRTX) Q2 Earnings andand Sales Beat, Revenue Guidance Up

Fri, 31 Jul 2020 16:33:04 Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.... Read Full Article

Dow Jones Futures Signal Stock Market Rally After Apple, Amazon, Facebook, Google Earnings

Fri, 31 Jul 2020 12:20:35 Futures rose Friday, signaling further gains for the coronavirus stock market rally on Apple, Amazon, Facebook and Google earnings.... Read Full Article

How Vertex Pharmaceuticals Wowed With Its Q2 Results

Fri, 31 Jul 2020 10:42:00 Vertex Pharmaceuticals (NASDAQ: VRTX) has been on a roll so far in 2020. The company announced its second-quarter results after the market closed on Thursday. It looks like Vertex's good times will keep rolling.... Read Full Article

Vertex Pharmaceuticals Inc (VRTX) Q2 2020 Earnings Call Transcript

Fri, 31 Jul 2020 07:31:44 VRTX earnings call for the period ending June 29, 2020.... Read Full Article

10 Biggest Biotechnology Companies

Thu, 30 Jul 2020 23:32:40 With Novo Nordisk at the top of the list, these are the 10 biggest biotechnology companies by 12-month trailing revenue.... Read Full Article

Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates

Thu, 30 Jul 2020 21:35:09 Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Vertex Reports Second-Quarter 2020 Financial Results

Thu, 30 Jul 2020 20:01:00 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for total cystic fibrosis (CF) product revenues.... Read Full Article

Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX andand More

Wed, 29 Jul 2020 15:24:03 Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.... Read Full Article

Why Vertex (VRTX) Could Beat Earnings Estimates Again

Mon, 27 Jul 2020 16:10:04 Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.... Read Full Article

Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases.

Sat, 25 Jul 2020 15:52:00 Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies.... Read Full Article

3 Stocks Immune to the Coronavirus

Sat, 25 Jul 2020 14:04:00 These companies kept sales on track through the lockdowns -- and they also have what it takes to keep revenue growing in the long term.... Read Full Article

3 Unstoppable Stocks to Buy Before the Next Market Crash

Sat, 25 Jul 2020 11:30:00 The healthcare industry is a good place to shop for stocks to keep your portfolio healthy during the next market crash.... Read Full Article

Stocks To Watch With Next Quarterly Report On Tap: Vertex Pharmaceuticals

Fri, 24 Jul 2020 23:47:00 IBD 50 and Sector Leaders member Vertex Pharmaceuticals (VRTX) is expected to report earnings on Jul. 30. Itand's trading now trading 6% below the 295.65 buy point from a second-stage flat base that it cleared earlier. Understand that buying a stock just before it ...... Read Full Article

Can Trikafta Drive Vertexand's (VRTX) Revenues in Q2 Earnings?

Fri, 24 Jul 2020 16:45:04 On Vertexand's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.... Read Full Article

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Thu, 23 Jul 2020 16:33:04 Vertex (VRTX) doesnand't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.... Read Full Article

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Wed, 22 Jul 2020 21:45:09 In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $291.23, marking a -0.06% move from the previous day.... Read Full Article

Dow Jones Surpasses 27,000 On 3rd Straight Gain; This Medical Stock Shines After Earnings

Wed, 22 Jul 2020 20:48:12 While the Dow Jones Industrial Average finished up 0.6%, the Nasdaq cut its early mild losses to close ahead 0.2%.... Read Full Article

Dow Jones Jumps Over 300 Points On Coronavirus Stimulus; Coca-Cola, IBM Rally On Earnings, While Lululemon, Vertex In New Buy Zones

Tue, 21 Jul 2020 16:05:51 The Dow Jones Industrial Average rallied 300 points early Tuesday after the European Union agreed to a coronavirus stimulus fund.... Read Full Article

Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation

Mon, 20 Jul 2020 13:00:00 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) ages 12 years and older who have one copy of the F508del mutation and ...... Read Full Article
<